166 related articles for article (PubMed ID: 32269062)
1. Morphological change and recovery of corneal endothelial cells after rho-associated protein kinase inhibitor eye-drop (ripasudil 0.4%) instillation.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Yoshikawa H; Sotozono C; Kinoshita S
Br J Ophthalmol; 2021 Feb; 105(2):169-173. PubMed ID: 32269062
[TBL] [Abstract][Full Text] [Related]
2. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
[No Abstract] [Full Text] [Related]
4. Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor.
Matsumura R; Inoue K; Shiokawa M; Ono M; Tanihara H; Ishida K; Tomita G
Int Ophthalmol; 2020 Feb; 40(2):411-417. PubMed ID: 31664638
[TBL] [Abstract][Full Text] [Related]
5. Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study.
Nakagawa H; Koizumi N; Okumura N; Suganami H; Kinoshita S
PLoS One; 2015; 10(9):e0136802. PubMed ID: 26367375
[TBL] [Abstract][Full Text] [Related]
6. Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells.
Okumura N; Okazaki Y; Inoue R; Nakano S; Fullwood NJ; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7560-7. PubMed ID: 26618648
[TBL] [Abstract][Full Text] [Related]
7. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
[TBL] [Abstract][Full Text] [Related]
8. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
[TBL] [Abstract][Full Text] [Related]
9. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine.
Chihara E; Dimitrova G; Chihara T
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1257-1264. PubMed ID: 29520478
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial.
Sakamoto E; Ishida W; Sumi T; Kishimoto T; Tada K; Fukuda K; Yoneda T; Kuroiwa H; Terao E; Fujisawa Y; Nakakura S; Jian K; Okumichi H; Kiuchi Y; Fukushima A
Sci Rep; 2019 Mar; 9(1):3755. PubMed ID: 30842572
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing.
Okumura N; Okazaki Y; Inoue R; Kakutani K; Nakano S; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1284-92. PubMed ID: 26998714
[TBL] [Abstract][Full Text] [Related]
15. Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil.
Saito H; Kagami S; Mishima K; Mataki N; Fukushima A; Araie M
J Glaucoma; 2019 Apr; 28(4):289-293. PubMed ID: 30720574
[TBL] [Abstract][Full Text] [Related]
16. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
Terao E; Nakakura S; Fujisawa Y; Fujio Y; Matsuya K; Kobayashi Y; Tabuchi H; Yoneda T; Fukushima A; Kiuchi Y
Curr Eye Res; 2017 May; 42(5):738-742. PubMed ID: 27911106
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
Goda E; Hirooka K; Mori K; Kiuchi Y
BMC Ophthalmol; 2019 Dec; 19(1):243. PubMed ID: 31791272
[TBL] [Abstract][Full Text] [Related]
18. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
Williams RD; Novack GD; van Haarlem T; Kopczynski C;
Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
[TBL] [Abstract][Full Text] [Related]
19. Effect of ripasudil on diabetic macular edema.
Minami Y; Song YS; Ishibazawa A; Omae T; Ro-Mase T; Ishiko S; Yoshida A
Sci Rep; 2019 Mar; 9(1):3703. PubMed ID: 30842496
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
